Ilana Fogelman

Dr. Fogelman co-founded LTR with Dr. Braunstein in 2004 and through LTR was involved in the formation of C₂N Diagnostics. She specializes in corporate and product pipeline valuation, drug development, clinical trial design and analysis, and FDA regulations. Dr. Fogelman is an expert in regulatory strategies and risk, and interpreting FDA actions, decisions, and requirements. From 1999 to 2003, Dr. Fogelman worked as a biotechnology analyst for Merrill Lynch and Salomon Smith Barney, covering small- to mid-cap public companies. From 1993 to 1999, Dr. Fogelman worked as a medical reviewer for FDA's Center for Biologics Evaluation and Research, focusing on new products for infectious diseases, autoimmune and inflammatory disorders. In that position, she reviewed more than 80 INDs, 2 BLAs, and 2 BLA supplements for a variety of technologies, including monoclonal antibodies, cytokines, immunomodulators, cell and gene therapies, and vaccine therapies. While at the FDA, Dr. Fogelman was also the Principal Investigator of an HIV clinical trial, which she designed and implemented in collaboration with the NIH to evaluate the immunologic reconstitution of HIV-infected patients receiving highly active antiretroviral therapies. Dr. Fogelman obtained her M.D. from the University of São Paulo (Brazil) and a Master in Public Health from Harvard University. At Harvard, she also completed two postdoctoral research fellowships in HIV clinical trials and immunology.